Application of lenalidomide maintenance therapy in diffuse large B-cell lymphoma patients after first-line treatment response
Objective To investigate the application effect of lenalidomide maintenance therapy in diffuse large B-cell lymphoma(DLBCL)patients after first-line treatment response.Method A total of 166 patients with DLBCL after first-line treatment response were divided into observation group(105 cases)and control group(61 cases)according to whether lenalidomide maintenance treatment was used.Observation group received lenalidomide maintenance treatment,control group did not receive maintenance treatment.The clinical characteristics,survival,incidences of venous thrombo-embolism(VTE)and cardiovascular disease were compared between the observation group and the control group.Ac-cording to the diagnosis results of deep vein ultrasound,the observation group was divided into VTE group(22 cases)and non-VTE group(83 cases).The clinical characteristics and survival were compared between the VTE group and the non-VTE group.Result There were statistically significant differences in age,economic status,DLBCL type,international prognostic index(IPI)stratification,lactate dehydrogenase(LDH)for the first time,final efficacy and cardiovascular dis-ease between observation group and control group(P＜0.05).There were no significant differences in 1-year and 2-year survival rates between observation group and control group(P＞0.05).The incidences of VTE and cardiovascular disease in observation group were significantly higher than those in control group,the differences were statistically significant(P＜0.01).There were significant differences in age,lenalidomide maintenance dose and course of treatment between VTE group and non-VTE group(P＜0.05).The 1-year survival rate of non-VTE group was higher than that of VTE group,and the difference was statistically significant(P＜0.05).Conclusion Lenalidomide maintenance treatment can improve the efficacy of DLBCL patients after first-line treatment response.Clinical attention and management of VTE and cardiovas-cular disease should be strengthened in the early stage of treatment.
diffuse large B-cell lymphomalenalidomidemaintenance treatmentvenous thromboembolism
万方数据
维普
